Let ’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia
Conclusion: In the current manuscript, we present blinatumomab as a therapeutic alternative in the bridge-to-transplant setting for refractory or relapsed ALL, to gain a better understanding of the available therapies and evidence-based data for these patients in 2019.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Allergy & Immunology | Chemotherapy | Clinical Trials | Immunotherapy | Leukemia | Romania Health | Transplants